Description
Summary Information: Velpacruz S is a combination medication provided in the form of oral tablets, containing two active substances: Sofosbuvir (400mg) and Velpatasvir (100mg). This combination medication is primarily used for the treatment of chronic hepatitis C virus (HCV) infection in adults. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, while Velpatasvir is a pan-genotypic NS5A inhibitor. Together, they work by targeting different stages of the HCV replication cycle, resulting in a potent antiviral effect and high cure rates across various HCV genotypes.
Product Composition: Each Velpacruz S tablet contains a fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg). Sofosbuvir inhibits the replication of the HCV RNA polymerase, while Velpatasvir interferes with the assembly and release of viral particles, thereby blocking viral replication and reducing viral load in the body. In addition to the active ingredients, Velpacruz S tablets may contain various excipients and coatings to ensure proper formulation and stability.
Manufacturer: Velpacruz S tablets are manufactured by Torrent Pharmaceuticals Ltd, a leading Indian pharmaceutical company known for its high-quality generic medications and innovative pharmaceutical formulations. Torrent Pharmaceuticals Ltd is committed to ensuring product efficacy, safety, and compliance with regulatory standards.
Package: Velpacruz S tablets are typically supplied in packs containing 28 tablets. Each tablet contains the fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg). The packaging may include information such as the expiration date, lot number, and manufacturer details.
Usage Instructions: Velpacruz S tablets are taken orally with water, usually once daily, or as directed by a healthcare professional experienced in the management of chronic HCV infection. The recommended treatment duration and regimen may vary depending on factors such as the HCV genotype, treatment history, and presence of liver cirrhosis. It is essential to follow the prescribed regimen closely and not to miss any doses to achieve optimal treatment outcomes.
Benefits:
- High Cure Rates: Velpacruz S offers high cure rates (>95%) across various genotypes of chronic HCV infection, including patients with or without liver cirrhosis.
- Pan-Genotypic Efficacy: The combination of Sofosbuvir and Velpatasvir provides pan-genotypic coverage, making it effective against HCV genotypes 1-6 without the need for genotype testing.
- Convenient Once-Daily Dosing: Velpacruz S tablets are administered orally once daily, offering convenience and ease of administration for patients undergoing HCV treatment.
- Improved Safety Profile: Velpacruz S is generally well-tolerated, with minimal adverse effects, making it suitable for long-term use in the management of chronic HCV infection.
It is important to note that Velpacruz S should only be used under the supervision of a qualified healthcare professional experienced in the management of chronic hepatitis C infection. Patients should be monitored regularly for treatment response, liver function, and potential adverse effects, and appropriate supportive care should be provided as needed throughout the course of treatment.
Reviews
There are no reviews yet.